Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713037 · ClinicalTrials.gov registry record · NA
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
A NA study of Chordoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00713037: Completed NA study of Chordoma, sponsored by Massachusetts General Hospital.
NCT00713037 is a NA study of Chordoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00713037, a NA study of Chordoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.
Conditions Studied
Interventions
- PROCEDURE Fluoromisonidazole-PET/CT
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713037
The ClinicalTrials.gov registry entry for NCT00713037 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (77% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 1 intervention - of which Fluoromisonidazole-PET/CT is the first listed.
NCT00713037 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00713037 about?
NCT00713037 is a clinical study titled "Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas". Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is...
What is the current status of trial NCT00713037?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2016-06.
What conditions does trial NCT00713037 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT00713037?
The interventions under investigation include: Fluoromisonidazole-PET/CT (PROCEDURE).
Who is sponsoring clinical trial NCT00713037?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00713037 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Body Radiotherapy for Spine Tumors
COMPLETED · NA
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.